Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

First-ever Mantle Cell Lymphoma Symposium to be held on Nov. 12

The Lymphoma Division of the John Theurer Cancer Center at Hackensack University Medical Center with the participation from the Facebook groups "Hope for Lymphoma" and "Our MCL Family," will host its first-ever Mantle Cell Lymphoma Symposium on Saturday, November 12 from 8:30am - 3:45pm.

8 Nov 2011

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

Pfizer Oncology will present data on a number of investigational compounds from its hematology portfolio, including new data from bosutinib in chronic myeloid leukemia (CML), inotuzumab in non-Hodgkin lymphoma (NHL), as well as the first presentation of clinical data for PF-04449913, which inhibits Smoothened (SMO), a key component of the Hedgehog pathway.

7 Nov 2011

Osiris Therapeutics third quarter revenues decrease marginally to $10.6 million

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory and cardiovascular disease areas and wound healing, announced today its results for the third quarter ended September 30, 2011.

4 Nov 2011

Inserm researchers successfully rejuvenate cells from elderly donors

Inserm's AVENIR "Genomic plasticity and aging" team, directed by Jean-Marc Lemaitre, Inserm researcher at the Functional Genomics Institute, has recently succeeded in rejuvenating cells from elderly donors.

4 Nov 2011

Pfizer, Sanford-Burnham to partner on translational medicine research

Sanford-Burnham Medical Research Institute is the latest research organization to partner with Pfizer, Inc. as part of Pfizer's commitment to transforming research and development through a focus on translational medicine.

4 Nov 2011

Gene therapy and stem cell transplantation successfully reverse hemophilia A

For the first time, researchers have combined gene therapy and stem cell transplantation to successfully reverse the severe, crippling bleeding disorder hemophilia A in large animals, opening the door to the development of new therapies for human patients.

3 Nov 2011

New study in fruit flies offers clues to delay human aging

One of the few reliable ways to extend an organism's lifespan, be it a fruit fly or a mouse, is to restrict calorie intake. Now, a new study in fruit flies is helping to explain why such minimal diets are linked to longevity and offering clues to the effects of aging on stem cell behavior.

3 Nov 2011

Elsevier's 2012 eBook Frontlist collections available on SciVerse ScienceDirect

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, announced today that its 2012 eBook Frontlist collections are available for advance purchase on SciVerse ScienceDirect, Elsevier's online platform for scientific content.

3 Nov 2011

MSCs can be reprogrammed to have enhanced survival and therapeutic efficacy

Chinese stem cell scientists have published new research that improves the survival and effectiveness of transplanted stem cells. The research led by Dr Hsiao Chang Chan, from the Chinese University of Hong Kong, is published in Stem Cells.

3 Nov 2011

Celldex third quarter net loss increases to $11.8 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2011. Celldex reported a net loss of $11.8 million, or $0.27 per share, for the third quarter of 2011 compared to a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010.

2 Nov 2011

Radiation therapy prior to HCT improves outcomes in older patients with hematologic malignancies

Older patients with advanced hematologic malignancies, such as leukemia and lymphoma, who received a conditioning regimen that included minimal-intensity radiation therapy prior to allogeneic hematopoietic cell transplantation had survival and progression-free survival outcomes suggesting that this treatment approach may be a viable option for older patients with these malignancies, according to a study in the November 2 issue of JAMA.

2 Nov 2011

Age is no longer a barrier to allogeneic stem cell transplantation

Age alone no longer should be considered a defining factor when determining whether an older patient with blood cancer is a candidate for stem cell transplantation. That's the conclusion of the first study summarizing long-term outcomes from a series of prospective clinical trials of patients age 60 and over who were treated with the mini-transplant, a "kinder, gentler" form of allogeneic (donor cell) stem cell transplantation developed at Fred Hutchinson Cancer Research Center.

2 Nov 2011

Young microenvironment rejuvenates old stem cells

Old stem cells can be rejuvenated by being placed in a young microenvironment, research from The University of Texas Health Science Center San Antonio shows. This raises the possibility that patients' own stem cells may one day be rescued and banked to treat their age-related diseases.

2 Nov 2011

First study to show how H. pylori toxin can spur apoptosis

Researchers report they have figured out how the cancer-causing bacterium Helicobacter pylori attacks a cell's energy infrastructure, sparking a series of events in the cell that ultimately lead it to self-destruct.

2 Nov 2011

Researchers develop new 3D bone marrow culture systems

Stromal cells, as distinct from hematopoietic cells, are an essential component of the bone marrow microenvironment and are necessary for the long-term maintenance of hematopoietic stem cells (HSCs) in vitro.

2 Nov 2011

$Adiponectin linked to osteoporosis and increased risk of fractures$

Adiponectin linked to osteoporosis and increased risk of fractures

While obesity is a well-known cause of cardiovascular disease, research from the Sahlgrenska Academy at the University of Gothenburg, Sweden, has now revealed that the body's obesity hormones - adiponectin - are also linked to osteoporosis and an increased risk of fractures.

2 Nov 2011

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.

2 Nov 2011

Positive results from DARA's DB959 Phase 1b study on type 2 diabetes

DARA BioSciences, Inc., announces the positive results from a successfully completed Phase 1b clinical study for DB959, its peroxisome proliferator activated receptor (PPAR)-delta/gamma agonist, a non-TZD oral drug in development for the treatment of type 2 diabetes.

2 Nov 2011

Ultra-sensitive techniques for early detection of breast cancer

A team of scientists at Tufts University will develop ultra-sensitive techniques at the single-molecule and single-cell levels designed to detect breast cancer earlier, and treat it with greater precision, through a $6.6 million Innovator Award from the Department of Defense Breast Cancer Research Program made to Tufts chemist David R. Walt, Ph.D.

1 Nov 2011

Tregs expansion can help prevent graft-versus-host disease

Graft-versus-host disease (GVHD) is a serious risk in many kinds of cell transplants, including for stem cell transplants carried out when stem cells are partially depleted of conventional T cells, which play an important role in the immune system. Now, researchers at Moffitt Cancer Center have tested a process by which T regulatory cells (Tregs) can be "expanded" to help prevent GVHD.

1 Nov 2011